NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled